DexCom reported strong third-quarter 2025 results with 20% organic revenue growth, driven by expanding customer access and innovative product offerings in the continuous glucose monitoring (CGM) space.

• Achieved 20% organic revenue growth year-over-year, reflecting robust market demand and competitive positioning.
• Expanded CGM access to nearly 6 million U.S. type 2 diabetes patients, targeting full coverage for over 25 million individuals.
• Introduced DexCom Smart Basal, an innovative titration module designed to enhance basal insulin management and improve patient adherence.
• Stelo product surpassed $100 million in revenue within its first year, indicating strong market traction and consumer interest in CGM for metabolic health.
• Continued advancement of G7 15-day system rollout, bolstered by successful reimbursement strategies.